October 22, 2008
PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
MIDLOTHIAN, Va., Oct. 22 /PRNewswire/ -- At CHEST 2008, PARI Respiratory Equipment will present a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca).
"Our goal in testing various breath-enhanced nebulizers is to help clinicians consider respirable drug delivery rate to ensure patients receive clinically effective doses," said Lisa Cambridge, director of clinical development for PARI Respiratory Equipment, Inc.
About PARI Respiratory Equipment, Inc.
PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.
Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDI's). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at http://www.pari.com/
Additional information is available by contacting Ayars & Associates at 805-845-5682 or Ashley Weigand at 804-253-7274 x711.
PARI Respiratory Equipment, Inc.
CONTACT: Ayars & Associates, +1-805-845-5682, or Ashley Weigand,+1-804-253-7274, ext. 711, both for PARI Respiratory Equipment, Inc.
Web site: http://www.pari.com/